BioCentury | Jul 17, 2020
Product Development

Vaccine developments in China include IND acceptance for Fosun, Phase II start for Chongqing Zhifei

...to a subset type of interferon responses as a potential target for treating severe COVID-19. Assistance Publique - Hopitaux de Paris...
...Hongjiang Li, Staff Writers WP1122 BioNTech SE U.S. Food and Drug Administration (FDA) NMPA Shanghai Fosun Pharmaceutical Group Co. Ltd. Pfizer Inc. Assistance Publique - Hopitaux de Paris Institut...
BioCentury | Feb 1, 2019
Company News

Inotrem gains rights to TREM1 biomarker for cardiovascular diseases

Inotrem S.A. (Paris, France) gained exclusive, worldwide rights to the soluble triggering receptor expressed on myeloid cells 1 (TREM1) biomarker for use in cardiovascular diseases, specifically acute myocardial infarction (MI), from the Universities of Paris...
BioCentury | Jun 8, 2018
Clinical News

Pfizer's Sutent improves survival without surgery in RCC patients

...and postoperative morbidity Status: Phase III data Milestone: NA Brian Moy Sutent, sunitinib (SU11248) American Society of Clinical Oncology ASCO Assistance Publique - Hopitaux de Paris Pfizer...
BioCentury | Jun 3, 2018
Clinical News

Pfizer's Sutent improves survival without surgery

Data from the Phase III CARMENA trial evaluating Sutent sunitinib from Pfizer Inc. (NYSE:PFE) showed that patients with renal cell carcinoma could avoid nephrectomy without compromising survival. The data were presented Sunday at the American...
BioCentury | Jun 11, 2015
Targets & Mechanisms

GeNeuro goes retro

GeNeuro S.A. put human endogenous retroviruses on the map as drug targets for multiple sclerosis, but new data point to a pathological role for the viruses in a much broader spectrum of diseases. Now GeNeuro...
BioCentury | Nov 24, 2014
Emerging Company Profile

Progressive play

Medday S.A.S. is developing MD 1003, a concentrated formulation of D-biotin that targets a rate-limiting enzyme in myelination and could stop disease progression in advanced multiple sclerosis. Proof could come with Phase III data early...
BioCentury | Oct 13, 2014
Clinical News

Gamma-retrovirus gene therapy: Phase I/II data

...sponsored by Children's Hospital Boston, Great Ormond Street Hospital for Children NHS Foundation Trust and Assistance Publique - Hopitaux de Paris...
BioCentury | Dec 23, 2013
Clinical News

Mydicar: Phase II started

Celladon said investigators at Assistance Publique-Hopitaux de Paris began the double-blind, placebo-controlled, French Phase II AGENT-HF trial to evaluate a single intracoronary infusion of Mydicar in 44 patients with severe heart failure. Celladon has exclusive...
BioCentury | Oct 21, 2013
Company News

IntegraGen, Assistance Publique - Hopitaux de Paris, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Pa

...The company did not provide comment in time for publication. IntegraGen S.A. (Euronext:ALINT), Evry, France Assistance Publique - Hopitaux de Paris...
BioCentury | Nov 7, 2011
Clinical News

Antiretroviral therapy: Phase III data

Researchers at the hospital system and colleagues reported data from the open-label, Cambodian Phase III CAMELIA trial in 661 patients showing that initiating ART 2 weeks after the start of TB treatment significantly improved survival,...
Items per page:
1 - 10 of 15
BioCentury | Jul 17, 2020
Product Development

Vaccine developments in China include IND acceptance for Fosun, Phase II start for Chongqing Zhifei

...to a subset type of interferon responses as a potential target for treating severe COVID-19. Assistance Publique - Hopitaux de Paris...
...Hongjiang Li, Staff Writers WP1122 BioNTech SE U.S. Food and Drug Administration (FDA) NMPA Shanghai Fosun Pharmaceutical Group Co. Ltd. Pfizer Inc. Assistance Publique - Hopitaux de Paris Institut...
BioCentury | Feb 1, 2019
Company News

Inotrem gains rights to TREM1 biomarker for cardiovascular diseases

Inotrem S.A. (Paris, France) gained exclusive, worldwide rights to the soluble triggering receptor expressed on myeloid cells 1 (TREM1) biomarker for use in cardiovascular diseases, specifically acute myocardial infarction (MI), from the Universities of Paris...
BioCentury | Jun 8, 2018
Clinical News

Pfizer's Sutent improves survival without surgery in RCC patients

...and postoperative morbidity Status: Phase III data Milestone: NA Brian Moy Sutent, sunitinib (SU11248) American Society of Clinical Oncology ASCO Assistance Publique - Hopitaux de Paris Pfizer...
BioCentury | Jun 3, 2018
Clinical News

Pfizer's Sutent improves survival without surgery

Data from the Phase III CARMENA trial evaluating Sutent sunitinib from Pfizer Inc. (NYSE:PFE) showed that patients with renal cell carcinoma could avoid nephrectomy without compromising survival. The data were presented Sunday at the American...
BioCentury | Jun 11, 2015
Targets & Mechanisms

GeNeuro goes retro

GeNeuro S.A. put human endogenous retroviruses on the map as drug targets for multiple sclerosis, but new data point to a pathological role for the viruses in a much broader spectrum of diseases. Now GeNeuro...
BioCentury | Nov 24, 2014
Emerging Company Profile

Progressive play

Medday S.A.S. is developing MD 1003, a concentrated formulation of D-biotin that targets a rate-limiting enzyme in myelination and could stop disease progression in advanced multiple sclerosis. Proof could come with Phase III data early...
BioCentury | Oct 13, 2014
Clinical News

Gamma-retrovirus gene therapy: Phase I/II data

...sponsored by Children's Hospital Boston, Great Ormond Street Hospital for Children NHS Foundation Trust and Assistance Publique - Hopitaux de Paris...
BioCentury | Dec 23, 2013
Clinical News

Mydicar: Phase II started

Celladon said investigators at Assistance Publique-Hopitaux de Paris began the double-blind, placebo-controlled, French Phase II AGENT-HF trial to evaluate a single intracoronary infusion of Mydicar in 44 patients with severe heart failure. Celladon has exclusive...
BioCentury | Oct 21, 2013
Company News

IntegraGen, Assistance Publique - Hopitaux de Paris, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Pa

...The company did not provide comment in time for publication. IntegraGen S.A. (Euronext:ALINT), Evry, France Assistance Publique - Hopitaux de Paris...
BioCentury | Nov 7, 2011
Clinical News

Antiretroviral therapy: Phase III data

Researchers at the hospital system and colleagues reported data from the open-label, Cambodian Phase III CAMELIA trial in 661 patients showing that initiating ART 2 weeks after the start of TB treatment significantly improved survival,...
Items per page:
1 - 10 of 15